2: Toripalimab Plus Celecoxib Improves pCR in dMMR Locally Advanced Colorectal Cancer
A phase 2 clinical trial published in The Lancet Oncology indicates that combining toripalimab with celecoxib improves pathological complete response in patients with dMMR or MSI-H colorectal cancer. The study suggests that COX-2 inhibition may enhance the efficacy of immune checkpoint blockade.
Neoadjuvant immune checkpoint blockade has shown strong activity in mismatch repair-deficient or microsatellite instability-high locally advanced colorectal cancer. The PICC-2 trial evaluated whether adding the COX-2 inhibitor celecoxib to neoadjuvant toripalimab could further improve pathological complete response in this setting.
Get the full story
Sign up for Headlinne to unlock AI insights, political bias analysis, and your personalized news feed.
Create free accountAlready have an account? Sign in